Skip to main content

Advertisement

SpringerLink
Log in

The 28th Annual San Antonio Breast Cancer Symposium (SABCS)

8–11 December 2005, San Antonio, Texas, USA

  • Meeting Report
  • Published:
American Journal of Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Jonat W, Gnant M, Boccardo F, et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial [abstract no. 18]. Breast Cancer Res Treat 2005; 94Suppl. 1: 11(plus oral presentation)

    Google Scholar 

  2. Goss PE, Ingle JN, Palmer MJ, et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding [abstract no. 16]. Breast Cancer Res Treat 2005; 94Suppl. 1: 10–11(plus oral presentation)

    Google Scholar 

  3. Jones SE, Savin MA, Holmes FA, et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer [abstract no. 40]. Breast Cancer Res Treat 2005; 94Suppl. 1: 20(plus oral presentation)

    Google Scholar 

  4. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACRmT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACRmTH) with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study [abstract no. 1]. Breast Cancer Res Treat 2005; 94Suppl. 1: 5(plus oral presentation)

    Google Scholar 

  5. Kim C, Bryant J, Home Z, et al. Trastuzumab sensitivity of breast cancer with coamplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo [abstract]. Breast Cancer Res Treat 2005; 94Suppl. 1: 6

    Google Scholar 

  6. Burstein HJ, Spigel D, Kindsvogel K, et al. Metronomic chemotherapy with and without bevicizumab for advanced breast cancer: a randomized phase II study [abstract no. 4]. Breast Cancer Res Treat 2005; 94Suppl. 1: 6(plus oral presentation)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Ltd., 770 Township Line Road, Suite 300, Yardley, PA, 19067, USA

    Melanie Sweetlove &  Michelle Wilde

Authors
  1. Melanie Sweetlove
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Wilde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sweetlove, M., Wilde, M. The 28th Annual San Antonio Breast Cancer Symposium (SABCS). Am J Cancer 5, 137–139 (2006). https://doi.org/10.2165/00024669-200605020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200605020-00007

Keywords

Search

Navigation